Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

BEIJING, April 13, 2026 /PRNewswire/ — On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of […]